Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients.
Claudia ArenaGiuseppe TroianoAlfredo De LilloNunzio F TestaLorenzo Lo MuzioPublished in: BioMed research international (2018)
Analysis of the reports with patients treated with sunitinib, sorafenib, axitinib, and cabozantinib showed a clear prevalence of stomatitis grade 1 or grade 2. These data differ from those of patients treated with conventional chemotherapy in which mucositis is predominantly of grade 3 or grade 4.
Keyphrases
- machine learning
- end stage renal disease
- metastatic renal cell carcinoma
- deep learning
- chronic kidney disease
- ejection fraction
- newly diagnosed
- systematic review
- risk factors
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- emergency department
- radiation therapy
- patient reported outcomes
- virtual reality
- rectal cancer